75.2 F
Miami
Thursday, October 6, 2022

New omicron-specific COVID booster expected to be approved before trial data is in

The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans.

The shots, modified to target the latest versions of the omicron variant, won’t have finished testing in humans when the FDA makes its decisions.

Source

Related Articles

- Advertisement -

Latest Articles